fund
chongq
educ
board
new
coronaviru
infect
prevent
emerg
scientif
research
project
chongq
scienc
technolog
bureau
new
crown
pneumonia
epidem
emerg
scienc
technolog
special
fourth
batch
project
famou
teacher
project
chongq
talent
plan
right
reserv
reus
allow
without
permiss
background
sever
acut
respiratori
syndrom
coronaviru
novel
betacoronaviru
caus
outburst
pneumonia
case
wuhan
china
report
product
specif
igm
igg
antibodi
infect
implic
diagnosi
patholog
cours
diseas
well
recurr
posit
nucleic
acid
test
discharg
method
test
result
igm
igg
antibodi
confirm
patient
retrospect
examin
clinic
data
collect
analyz
base
variou
subgroup
igm
igg
antibodi
determin
chemiluminesc
method
find
concentr
sco
igm
igg
antibodi
peak
day
symptom
onset
median
iqr
igm
iqr
igg
detect
rate
reach
highest
day
day
igm
igg
respect
significantli
higher
concentr
igg
critic
ill
patient
mild
moder
diseas
concentr
antibodi
day
correl
cours
outcom
diseas
spearman
r
p
nasopharyng
swab
reveal
posit
rna
recov
patient
discharg
whose
igg
prove
significantli
lower
neg
rna
result
p
igg
igm
test
twice
within
day
discharg
interv
second
test
antibodi
display
decreas
concentr
iqr
igg
iqr
igm
without
statist
signific
patient
redetect
posit
rna
result
neg
rna
result
discharg
howev
posit
result
experienc
count
decreas
lymphocyt
subset
interpret
concentr
igm
igg
antibodi
peak
day
symptom
onset
antibodi
test
day
associ
increas
detect
rate
antibodi
concentr
affect
cours
outcom
infect
recov
patient
redetect
posit
rna
display
lower
concentr
igg
downward
trend
igg
recoveri
indic
limit
durat
protect
protect
effect
igg
remain
investig
fund
chongq
educ
board
chongq
scienc
technolog
bureau
famou
teacher
project
chongq
talent
plan
right
reserv
reus
allow
without
permiss
corona
viru
diseas
covid
infect
sever
acut
respiratori
syndrom
coronaviru
spread
global
sinc
first
appear
wuhan
china
decemb
account
case
death
countri
area
territori
seventh
coronaviru
known
infect
human
sarscov
merscov
caus
sever
diseas
wherea
associ
mild
symptom
infect
provok
immunolog
defens
product
specif
antibodi
among
igm
antibodi
indic
current
recent
infect
earliest
develop
exposur
pathogen
igg
antibodi
common
antibodi
immunolog
respons
indic
recoveri
diseas
past
infect
therefor
test
igg
igm
antibodi
facilit
diagnosi
evalu
infect
statu
well
fact
test
igg
igm
antibodi
investig
regard
valu
earli
diagnosi
diseas
adopt
one
diagnosi
criteria
chines
guidelin
howev
product
antibodi
protect
effect
implic
outcom
associ
redetect
posit
rna
remain
clarifi
work
repres
retrospect
analysi
confirm
patient
chongq
china
antibodi
test
throw
light
develop
igg
igm
antibodi
associ
cours
outcom
diseas
redetect
posit
rna
test
discharg
studi
includ
confirm
patient
chongq
three
gorg
central
hospit
januari
rd
march
rd
among
mild
moder
case
mild
group
sever
critic
case
sever
group
femal
male
patient
averag
age
year
studi
approv
medic
ethic
committe
first
affili
hospit
chongq
medic
univers
approv
number
due
special
reason
epidem
patient
inform
consent
obtain
clinic
data
includ
epidemiolog
clinic
manifest
laboratori
cours
outcom
followup
collect
test
igg
igm
antibodi
perform
everi
day
post
symptom
onset
pso
result
analyz
product
detect
rate
differ
concentr
mild
group
sever
group
patient
initi
antibodi
test
result
upon
admiss
divid
accord
posit
neg
igm
posit
neg
calcul
accord
jiong
wu
et
al
relat
antibodi
concentr
durat
posit
viru
detect
durat
first
last
posit
nucleic
acid
test
durat
fever
durat
first
last
detect
fever
defin
temperatur
length
hospit
stay
progress
pii
pii
valu
day
admiss
minu
within
day
admiss
outcom
diseas
investig
antibodi
test
result
patient
day
symptom
onset
predict
valu
igg
igm
antibodi
concentr
redetect
posit
nucleic
acid
test
investig
antibodi
test
result
recov
patient
within
day
discharg
differ
antibodi
concentr
patient
without
redetect
posit
nucleic
acid
studi
two
repeat
antibodi
test
perform
day
day
interv
patient
lymphocyt
subset
patient
redetect
posit
nucleic
acid
examin
diagnosi
discharg
decis
made
accord
guidelin
diagnosi
treatment
novel
coronaviru
infect
nation
health
commiss
trial
version
suspect
case
subject
reversetranscript
polymeras
chain
reaction
rtpcr
document
case
categor
mild
moder
sever
critic
type
clinic
manifest
discharg
criteria
includ
normal
temperatur
last
day
signific
improv
respiratori
symptom
signific
improv
chest
radiolog
neg
nucleic
acid
test
two
consecut
respiratori
specimen
collect
interv
least
day
test
igg
igm
perform
serum
sampl
kept
min
use
cfda
approv
magnet
chemiluminesc
enzym
immunoassay
mclia
kit
suppli
bioscienc
co
ltd
chongq
china
follow
manufactur
instruct
mclia
igg
igm
detect
develop
base
doubleantibodi
sandwich
immunoassay
recombin
antigen
contain
nucleoprotein
peptid
spike
protein
conjug
fluorescein
isothiocyan
fitc
immobil
antifitc
antibodyconjug
magnet
particl
alkalin
phosphataseconjug
human
iggigm
antibodi
use
detect
antibodi
test
conduct
autom
magnet
chemiluminesc
analyz
axce
bioscienc
china
accord
manufactur
instruct
antibodi
level
express
ratio
chemiluminesc
signal
cutoff
valu
sco
sco
design
neg
otherwis
posit
statist
analysi
perform
use
sa
softwar
dynam
chang
antibodi
analyz
logarithm
igg
igm
valu
use
gener
linear
mix
model
map
local
weight
polynomi
regress
count
data
present
frequenc
percentag
compar
use
test
fisher
exact
test
measur
data
present
mean
standard
deviat
median
interquartil
rang
comparison
made
use
student
test
wilcoxon
rank
sum
test
accord
normal
data
correl
variabl
examin
spearman
rank
correl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
analysi
includ
test
result
patient
whose
characterist
list
supplementari
tabl
patient
sever
group
older
mild
group
differ
statist
signific
patient
diabet
cardiovascular
diseas
chronic
obstruct
pulmonari
diseas
prone
sever
critic
diseas
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
posit
rate
day
symptom
onset
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
similarli
correl
outcom
exacerb
improv
igg
igm
level
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
recov
patient
met
discharg
criteria
discharg
isol
medic
observ
day
present
redetect
posit
viru
nucleic
acid
period
patient
significantli
lower
igg
concentr
within
day
discharg
differ
igm
concentr
signific
decreas
igg
igm
antibodi
recov
patient
two
test
within
day
discharg
interv
statist
signific
respect
decreas
igg
igm
reach
iqr
iqr
tabl
addit
decreas
seen
count
total
lymphocyt
total
lymphocyt
lymphocyt
lymphocyt
total
b
lymphocyt
natur
killer
lymphocyt
variou
extent
account
patient
redetect
posit
viru
nucleic
acid
readmit
respect
supplementari
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
data
median
iqr
n
differ
two
antibodi
test
within
day
discharg
interv
decreas
antibodi
level
detect
within
day
discharg
interv
calcul
differ
result
two
antibodi
testsresult
first
antibodi
test
posit
case
recov
patient
redetect
nucleic
acid
nasopharyng
swab
within
day
discharg
neg
case
recov
patient
neg
nucleic
acid
nasopharyng
swab
within
day
discharg
epidem
escal
antibodi
test
includ
diagnost
procedur
accord
therefor
igg
igm
antibodi
test
combin
rtpcr
earli
diagnosi
method
patient
also
reveal
wors
prognosi
associ
higher
igg
concentr
therefor
protect
effect
igg
associ
deterior
lung
injuri
remain
explor
research
find
also
rais
question
valid
practic
treat
diseas
serum
recov
patient
despit
encourag
result
clinic
improv
critic
ill
patient
transfus
convalesc
plasma
contain
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
studi
demonstr
rate
redetect
posit
nucleic
acid
high
despit
strict
adher
domest
guidelin
discharg
criteria
may
attribut
fact
mainli
resid
lower
respiratori
system
addit
possibl
deviat
specimen
collect
may
lead
fals
neg
nucleic
test
consequ
inappropri
discharg
decis
result
recurr
even
deterior
diseas
patient
redetect
posit
nucleic
acid
display
declin
lymphocyt
subset
second
admiss
similar
chang
initi
infect
patient
nucleic
acid
detect
nasopharyng
swab
within
day
discharg
significantli
lower
igg
concentr
compar
neg
nucleic
acid
discharg
differ
igm
concentr
signific
meanwhil
chang
igg
igm
test
interv
display
signific
differ
therefor
repeat
nucleic
acid
test
conduct
use
specimen
collect
multipl
site
discharg
level
igg
may
contribut
discharg
criteria
result
also
suggest
possibl
igg
serv
protect
antibodi
also
bear
potenti
deterior
injuri
multipl
organ
proven
rais
concern
treatment
serum
antibodi
recov
patient
may
indic
igg
immun
complex
indic
evalu
organ
injuri
diseas
sever
qf
h
sl
g
made
substanti
contribut
studi
concept
design
qf
h
xz
l
charg
manuscript
draft
wh
h
x
w
lx
z
z
collect
confirm
data
accuraci
jy
appli
ethic
approv
b
p
qf
h
particip
statist
analysi
xp
c
qf
h
charg
laboratori
task
includ
sampl
process
detect
data
acquisit
interpret
l
gc
w
clinic
expert
charg
treatment
patient
sl
g
gc
w
made
substanti
revis
manuscriptal
author
contribut
data
acquisit
data
analysi
data
interpret
review
approv
final
version
author
declar
compet
interest
permiss
correspond
author
provid
particip
data
without
name
identifi
studi
protocol
statist
analysi
plan
inform
consent
form
data
provid
articl
publish
data
made
public
research
team
provid
email
address
commun
correspond
author
right
decid
whether
share
data
base
research
object
plan
provid
